In a closely watched pharmaceutical patent dispute, Intercept Pharmaceuticals, Inc. secured a consent judgment and permanent injunction against Zenara Pharma Private Limited in the Delaware District Court, effectively blocking Zenara’s generic obeticholic acid tablets from reaching the U.S. market without authorization. Filed on September 16, 2022, and resolved on March 6, 2024 — after 537 days of litigation — the case centered on six patents protecting Intercept’s obeticholic acid franchise, the active ingredient in Ocaliva®, a treatment for primary biliary cholangitis (PBC).

This obeticholic acid patent infringement case exemplifies the high-stakes ANDA (Abbreviated New Drug Application) litigation landscape where branded pharmaceutical companies deploy broad patent portfolios to defend market exclusivity. For patent attorneys, IP professionals, and R&D teams, the outcome carries meaningful lessons about multi-patent assertion strategies, consent judgment mechanics, and the enduring power of negotiated settlements in Hatch-Waxman litigation.

Case Overview

The Parties

The Patents at Issue

This landmark case involved six U.S. patents covering obeticholic acid compositions, formulations, and methods of treatment, forming a layered exclusivity strategy. These patents protect the active ingredient in Ocaliva®, a treatment for primary biliary cholangitis (PBC).

• • US9238673B2 (Composition & Methods)
• • US10047117B2 (Formulation & Methods)
• • US10052337B2 (Dosage Forms & Methods)
• • US10174073B2 (Method of Treatment)
• • US10751349B2 (Compound & Composition)
• • US10758549B2 (Method of Use)

The Verdict & Legal Analysis

Outcome: Consent Judgment and Permanent Injunction

The parties negotiated a **Settlement Agreement** whose terms were embodied in a **Consent Judgment** entered by the District Court on March 6, 2024. Key elements include:

• Permanent Injunction: Zenara, its affiliates, successors, and assigns are enjoined from making, having made, using, selling, offering to sell, importing, or distributing the Zenara Products (5 mg and 10 mg obeticholic acid tablets under ANDA No. 214855), except as specifically authorized by the Settlement Agreement.
• FDA Approval Preserved: The Consent Judgment expressly permits the FDA to grant final approval to ANDA No. 214855 — meaning Intercept likely negotiated an authorized generic arrangement or a future market entry date, though specific financial terms were not publicly disclosed.
• Jurisdiction Retained: The court retained jurisdiction to enforce the Consent Judgment and supervise Settlement Agreement compliance.
• Dismissal With Prejudice: All claims, counterclaims, affirmative defenses, and demands were dismissed with prejudice, with no award of costs or attorneys’ fees to either party.

Verdict Cause Analysis

Because the case resolved via consent judgment rather than a contested ruling, no judicial findings on patent validity, infringement, or claim construction were issued. This is strategically significant: Zenara avoided an adverse merits ruling that could have created precedent useful to Intercept in future ANDA litigations involving the same patents. Simultaneously, Intercept preserved full patent enforceability against other generic challengers without the risk of an invalidity finding.

The breadth of Intercept’s six-patent assertion — spanning multiple application families and covering compound, formulation, and method claims — likely created substantial litigation risk for Zenara, making settlement economically rational. Multi-patent ANDA cases of this complexity routinely settle because the cost of challenging all asserted patents through claim construction and trial exceeds the expected value of winning even a subset of validity or non-infringement arguments.

Legal Significance

This case reinforces several important principles in pharmaceutical patent litigation:

1. Patent Portfolio Depth Drives Settlement Value: Asserting six patents across distinct claim categories significantly increases the generic challenger’s litigation burden and settlement probability.
2. Consent Judgments Preserve Optionality: By keeping FDA approval of ANDA No. 214855 expressly possible under the settlement, Intercept likely secured future licensing revenue rather than a permanent total bar — a commercially sophisticated resolution.
3. No Merits Precedent: The absence of claim construction or validity rulings means this case does not create citable precedent on obeticholic acid patent scope — which may encourage other ANDA filers to attempt similar challenges.